Thus, in the patient with diabetic nephropathy when RAAS blockade fails to return the urine albumin level to normal, the addition of a SGLT-2 antagonist or a mineralocorticoid receptor blocker can be added. This evidence concerns the gene SLC5A2 and diabetic kidney disease.